ARTELO BIOSCIENCES, INC. 8-K

What Happened
Artelo Biosciences, Inc. (ARTL) reported in an 8-K (filed Feb 5, 2026) that the Nasdaq Hearing Panel granted the company’s request for an exception to cure listing deficiencies, conditioned on the company demonstrating compliance with Nasdaq Listing Rule 5550(b)(1) (maintain stockholders’ equity of at least $2,500,000) by March 30, 2026. The Panel’s decision follows a prior delist determination the company received on November 19, 2025, and a hearing held on January 15, 2026. The filing also notes the company cured the Nasdaq Listing Rule 5620(a) deficiency (holding an annual meeting) after its 2025 annual meeting, which had been adjourned from December 31, 2025 to January 30, 2026 and was held on January 30, 2026.

Key Details

• Nasdaq condition: regain compliance with Listing Rule 5550(b)(1) (stockholders’ equity ≥ $2,500,000) by March 30, 2026.
• Company must file timely public disclosure describing the transactions used to achieve compliance and demonstrate long-term compliance after those transactions.
• Company previously received a delist determination from Nasdaq on November 19, 2025; a hearing occurred January 15, 2026.
• Annual Meeting Rule (Nasdaq 5620(a)) deficiency addressed: 2025 annual meeting was adjourned and then held on January 30, 2026.

Why It Matters
This filing notifies investors that Artelo remains at risk of delisting unless it documents and achieves the required $2.5M stockholders’ equity level by March 30, 2026. Delisting could materially affect the stock’s liquidity and market access; the Panel’s exception gives the company time but imposes a firm deadline and reporting requirements. The company says it will take reasonable measures to regain compliance, but provides no assurance it will succeed.